Keywords: wt-kras, erbitux, efficacy, biomarker, german, drugmaker, merck

wt-KRAS as Erbitux efficacy biomarker

Article | 04 February 2008

Print This

German drugmaker Merck KGaA says that data from three studies of the anticancer agent Erbitux (cetuximab) indicate that it is ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in